Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). (Q31018689)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). (English)

1 reference

Europe PubMed Central

13 August 2017

20

object named as

Jean-Yves Blay

0 references

Isabelle Ray-Coquard

2

object named as

Isabelle Ray-Coquard

0 references

Nadège Corradini

7

object named as

Nadège Corradini

0 references

Sophie Piperno-Neumann

12

object named as

Sophie Piperno-Neumann

0 references

Perrine Marec-Bérard

21

object named as

Perrine Marec-Bérard

0 references

Jacques-Olivier Bay

14

object named as

Jacques-Olivier Bay

1 reference

Europe PubMed Central

13 August 2017

4

object named as

Magali Girodet

1 reference

Europe PubMed Central

13 August 2017

Laurence Brugières

9

object named as

Laurence Brugieres

1 reference

Europe PubMed Central

13 August 2017

Jean-Claude Gentet

15

object named as

Jean-Claude Gentet

1 reference

Europe PubMed Central

13 August 2017

16

object named as

Antoine Thyss

1 reference

Europe PubMed Central

13 August 2017

Loïc Chaigneau

17

object named as

Loic Chaigneau

1 reference

Europe PubMed Central

13 August 2017

10

object named as

Julien Domont

1 reference

Europe PubMed Central

13 August 2017

11

object named as

Cyril Lervat

1 reference

Europe PubMed Central

13 August 2017

Perrine Marec-Bérard

21

object named as

Perrine Marec-Bérard

1 reference

Europe PubMed Central

13 August 2017

author name string

Mathilde Penel-Page

1

1 reference

Europe PubMed Central

13 August 2017

Julie Larcade

3

1 reference

Europe PubMed Central

13 August 2017

Laure Bouclier

5

1 reference

Europe PubMed Central

13 August 2017

Muriel Rogasik

6

1 reference

Europe PubMed Central

13 August 2017

Natacha Entz-Werle

8

1 reference

Europe PubMed Central

13 August 2017

Helène Pacquement

13

1 reference

Europe PubMed Central

13 August 2017

Bérangère Narciso

18

1 reference

Europe PubMed Central

13 August 2017

Helène Cornille

19

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

5 November 2015

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

15

1 reference

Europe PubMed Central

13 August 2017

854

1 reference

Europe PubMed Central

13 August 2017

https://scigraph.springernature.com/pub.10.1186/s12885-015-1894-5

0 references

The off-label use of targeted therapies in sarcomas: the OUTC'S program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Targeted therapy for sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

A role for maintenance therapy in managing sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

28 July 2018

Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

Bone sarcomas: from biology to targeted therapies.

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1894-5

21 January 2018

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635968

25 November 2018

153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26541413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/26541413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26541413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26541413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12885-015-1894-5

1 reference

Europe PubMed Central

13 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31018689&oldid=1835244145"